Incyte (INCY) Stock Forecast & Price Target

Compare

1,909 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INCY Analyst Ratings

Moderate Buy

9 Buy

7 Hold

1 Sell

Based on 17 analysts giving stock ratings to

Incyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INCY Stock 12 Month Forecast

Average Price Target

$109.20

▲(8.01% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $109.20 with a high forecast of $135.00 and a low forecast of $73.00. The average price target represents a 8.01% change from the last price of $101.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"$59","136":"$136","78.25":"$78.3","97.5":"$97.5","116.75":"$116.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":109.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$109.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$73.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,78.25,97.5,116.75,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.67,105.15692307692308,107.64384615384616,110.13076923076923,112.61769230769231,115.10461538461539,117.59153846153846,120.07846153846154,122.56538461538462,125.05230769230769,127.53923076923077,130.02615384615385,132.51307692307694,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.67,103.1723076923077,103.6746153846154,104.17692307692307,104.67923076923077,105.18153846153847,105.68384615384616,106.18615384615384,106.68846153846154,107.19076923076923,107.69307692307693,108.19538461538461,108.69769230769231,{"y":109.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.67,100.3876923076923,98.10538461538462,95.82307692307693,93.54076923076923,91.25846153846155,88.97615384615385,86.69384615384615,84.41153846153847,82.12923076923077,79.84692307692308,77.5646153846154,75.2823076923077,{"y":73,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":74.16,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.31,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.67,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$135.00

Average Price Target$109.20

Lowest Price Target$73.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Etzer Darout

Barclays

$116→$117

Buy

15.73%

Upside

Reiterated

02/18/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Incyte (NASDAQ: INCY) and Moderna (NASDAQ: MRNA)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$120

Buy

18.69%

Upside

Reiterated

02/11/26

Jefferies Keeps Their Buy Rating on Incyte (INCY)

Derek Archila

Wells Fargo

$107→$101

Hold

-0.10%

Downside

Reiterated

02/11/26

Wells Fargo Remains a Hold on Incyte (INCY)

Srikripa Devarakonda

Truist Financial

Hold

―

Reiterated

02/11/26

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Zimmer Biomet Holdings (NYSE: ZBH) and Theravance Biopharma (NASDAQ: TBPH)

Evan Seigerman

BMO Capital

$75

Sell

-25.82%

Downside

Reiterated

02/11/26

Incyte (INCY) Receives a Sell from BMO Capital

Salveen Richter

Goldman Sachs

$90→$98

Hold

-3.07%

Downside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Neuronetics (NASDAQ: STIM), Incyte (NASDAQ: INCY) and Zimmer Biomet Holdings (NYSE: ZBH)

Stephen Willey

Stifel Nicolaus

$119→$120

Buy

18.69%

Upside

Reiterated

02/11/26

Incyte price target raised to $120 from $119 at StifelIncyte price target raised to $120 from $119 at Stifel

Mitchell Kapoor

H.C. Wainwright

$135

Buy

33.53%

Upside

Reiterated

02/11/26

Incyte: Long-Term Revenue Durability and Underappreciated Pipeline Support Buy Rating and $135 Target

Judah Frommer

Morgan Stanley

$94→$102

Hold

0.89%

Upside

Reiterated

02/11/26

Incyte (INCY) Receives a Hold from Morgan Stanley

Michael Schmidt

Guggenheim

$125→$130

Buy

28.59%

Upside

Reiterated

02/10/26

Guggenheim Sticks to Its Buy Rating for Incyte (INCY)

Marc Frahm

TD Cowen

$128→$123

Buy

21.66%

Upside

Reiterated

02/10/26

Incyte (INCY) Receives a Buy from TD Cowen

Brian Abrahams

RBC Capital

$95→$92

Hold

-9.00%

Downside

Reiterated

02/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (NASDAQ: INCY), Edwards Lifesciences (NYSE: EW) and Royalty Pharma (NASDAQ: RPRX)

Matt Phipps

William Blair

Hold

―

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION) and Incyte (NASDAQ: INCY)

Tazeen Ahmad

Bank of America Securities

$118→$121

Buy

19.68%

Upside

Reiterated

02/10/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Exelixis (NASDAQ: EXEL), Incyte (NASDAQ: INCY) and Compass Therapeutics (NASDAQ: CMPX)

Allison Bratzel

Piper Sandler

$102→$110

Buy

8.80%

Upside

Reiterated

02/06/26

Incyte price target raised to $110 from $102 at Piper SandlerIncyte price target raised to $110 from $102 at Piper Sandler

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Etzer Darout

Barclays

$116→$117

Buy

15.73%

Upside

Reiterated

02/18/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Incyte (NASDAQ: INCY) and Moderna (NASDAQ: MRNA)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$120

Buy

18.69%

Upside

Reiterated

02/11/26

Jefferies Keeps Their Buy Rating on Incyte (INCY)

Derek Archila

Wells Fargo

$107→$101

Hold

-0.10%

Downside

Reiterated

02/11/26

Wells Fargo Remains a Hold on Incyte (INCY)

Srikripa Devarakonda

Truist Financial

Hold

―

Reiterated

02/11/26

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Zimmer Biomet Holdings (NYSE: ZBH) and Theravance Biopharma (NASDAQ: TBPH)

Evan Seigerman

BMO Capital

$75

Sell

-25.82%

Downside

Reiterated

02/11/26

Incyte (INCY) Receives a Sell from BMO Capital

Salveen Richter

Goldman Sachs

$90→$98

Hold

-3.07%

Downside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Neuronetics (NASDAQ: STIM), Incyte (NASDAQ: INCY) and Zimmer Biomet Holdings (NYSE: ZBH)

Stephen Willey

Stifel Nicolaus

$119→$120

Buy

18.69%

Upside

Reiterated

02/11/26

Incyte price target raised to $120 from $119 at StifelIncyte price target raised to $120 from $119 at Stifel

Mitchell Kapoor

H.C. Wainwright

$135

Buy

33.53%

Upside

Reiterated

02/11/26

Incyte: Long-Term Revenue Durability and Underappreciated Pipeline Support Buy Rating and $135 Target

Judah Frommer

Morgan Stanley

$94→$102

Hold

0.89%

Upside

Reiterated

02/11/26

Incyte (INCY) Receives a Hold from Morgan Stanley

Michael Schmidt

Guggenheim

$125→$130

Buy

28.59%

Upside

Reiterated

02/10/26

Guggenheim Sticks to Its Buy Rating for Incyte (INCY)

Marc Frahm

TD Cowen

$128→$123

Buy

21.66%

Upside

Reiterated

02/10/26

Incyte (INCY) Receives a Buy from TD Cowen

Brian Abrahams

RBC Capital

$95→$92

Hold

-9.00%

Downside

Reiterated

02/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (NASDAQ: INCY), Edwards Lifesciences (NYSE: EW) and Royalty Pharma (NASDAQ: RPRX)

Matt Phipps

William Blair

Hold

―

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION) and Incyte (NASDAQ: INCY)

Tazeen Ahmad

Bank of America Securities

$118→$121

Buy

19.68%

Upside

Reiterated

02/10/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Exelixis (NASDAQ: EXEL), Incyte (NASDAQ: INCY) and Compass Therapeutics (NASDAQ: CMPX)

Allison Bratzel

Piper Sandler

$102→$110

Buy

8.80%

Upside

Reiterated

02/06/26

Incyte price target raised to $110 from $102 at Piper SandlerIncyte price target raised to $110 from $102 at Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

3 Months

xxx

Success Rate

16/20 ratings generated profit

Average Return

+7.90%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +7.90% per trade.

1 Year

David LebowitzCiti

Success Rate

15/15 ratings generated profit

Average Return

+31.38%

a rating ―

Copying David Lebowitz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.38% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+57.95%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +57.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INCY Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INCY has received 22 Buy Ratings, 23 Hold Ratings, and 4 Sell Ratings. INCY average Analyst price target in the past 3 months is 109.20.

Each month's total comprises the sum of three months' worth of ratings.

INCY Financial Forecast

INCY Earnings Forecast

Next quarter’s earnings estimate for INCY is $1.43 with a range of $1.13 to $1.81. The previous quarter’s EPS was $1.80. INCY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year INCY has Performed in-line its overall industry.

INCY Sales Forecast

Next quarter’s sales forecast for INCY is $1.25B with a range of $1.17B to $1.33B. The previous quarter’s sales results were $1.51B. INCY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year INCY has Performed in-line its overall industry.

INCY Stock Forecast FAQ

What is INCY’s average 12-month price target, according to analysts?

Based on analyst ratings, Incyte Corp’s 12-month average price target is 109.20.

What is INCY’s upside potential, based on the analysts’ average price target?

Incyte Corp has 8.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INCY a Buy, Sell or Hold?

Incyte Corp has a consensus rating of Moderate Buy which is based on 9 buy ratings, 7 hold ratings and 1 sell ratings.

What is Incyte Corp’s price target?

The average price target for Incyte Corp is 109.20. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $135.00 ,the lowest forecast is $73.00. The average price target represents 8.01% Increase from the current price of $101.1.

What do analysts say about Incyte Corp?

Incyte Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of INCY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Incyte (INCY) Stock Forecast & Price Target

INCY Analyst Ratings

INCY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Incyte

INCY Analyst Recommendation Trends

INCY Financial Forecast

INCY Earnings Forecast

INCY Sales Forecast

INCY Stock Forecast FAQ

Detailed List of Analyst Forecasts